Q-omics provides the consensus-scored DNMT3A profile across patient tissues and cancer cell-line models. DNMT3A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DNMT3A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DNMT3A protein abundance shows 27,835 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where DNMT3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNMT3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNMT3A survival associations across molecular data types. DNMT3A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNMT3A RNA expression–survival associations across cancer types. High DNMT3A expression shows unfavorable associations in ACC, LIHC, MESO and LGG, but favorable associations in UCS and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DNMT3A RNA expression.
This table summarizes DNMT3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DNMT3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNMT3A shows higher tumor expression in HNSC, LIHC, LUAD, BLCA, LUSC and UCEC. The HNSC box plot shows higher DNMT3A RNA expression in tumor versus normal tissue (log2 FC = +0.730, t-test p < 0.001).
This table shows molecular features associated with DNMT3A in patient tissues and cancer cell lines. In patient samples, DNMT3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNMT3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
